Abstract
Background Ketamine has been shown to decrease sedative requirements in intensive care unit (ICU). Randomized trials are lacking on patient-centered outcomes. We aimed to compare the clinical characteristics and outcomes of mechanically ventilated adult ICU patients receiving ketamine as an adjunct analgosedative with those receiving standard of care (SOC) alone. We also described the feasibility during COVID-19 pandemic.
Methods In this randomized, open-label trial either ketamine or SOC, in a 1:1 ratio, was administered to patients who were intubated within 24 hours (medical, surgical, or transplant/oncology ICUs), expected to require mechanical ventilation (MV) for the next calendar day, and had the institutional pain and sedation protocol initiated. Ketamine infusion was 2 μg/kg/min on day 1 and 1 μg/kg/min on day 2. The primary outcome was the 28-day MV duration and ventilator-free days as co-primary outcome. Cox-proportional regression analysis was used to assess factors associated with probability for weaning off MV.
Results A total of 83 patients (43 in SOC and 40 in ketamine) were included. Demographics were balanced between the groups. The median duration of MV was not significantly different between the groups [median (interquartile range): 7 (3-9.25) for ketamine and 5 (2-8) for SOC, p= 0.15]. The median ventilation-free days was 19 days (IQR 0-24.75) in the ketamine and 19 days (IQR 0-24) in the SOC (p=0.70). Surgical and transplant/oncology ICU patients had a higher probability of weaning off MV than those in medical ICU [hazard ratio (95% confidence interval): 2.09 (1.06–4.14) for surgical ICU, 2.11 (1.02–4.35) for transplant/oncology ICU]. More patient was at goal RASS in ketamine compared to SOC. The sedatives and vasopressors cumulative doses were similar between the two arms at 48 hours. We found no difference in 28-day mortality rate, ICU and hospital length of stay, and hemodynamic changes. The consent rate was adequate and the protocol adherence rate was 97.5%.
Conclusions Ketamine as an adjunct agent for sedation did not decrease the duration of MV and appeared to be safe, feasible, and effective in subgroups of ICU patients. No effect was noted in sedative and pressors requirements, or on hemodynamics.
Trial registration ClinicalTrials.gov: NCT04075006 and current-controlled trials: ISRCTN14730035
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04075006
Funding Statement
No funding. This trial was investigator-initiated and all study authors are employees at King Faisal Specialist Hospital and Research Center (KFSH&RC), which has not provided any research grant for this particular project. All authors volunteered their time and used local resources to conduct the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with the principles of the Declaration of Helsinki. Our institution [King Faisal Specialist Hospital and Research Center (KFSH&RC)] research ethics committee (REC) and office of research affair approved the study with the Research Advisory Council (RAC) number 2191 187. Given the need to enroll patients in an expedited manner within the 24-hour window, verbal consent from a guardian/next of kin was allowed and documented in the chart. Written consent was obtained as soon as the next of kin became available. During the COVID-19 pandemic, where patients family visits were prohibited, we were unable to obtain written consent. Therefore, we granted approval from our research ethics committee for the following consenting process: verbal consent from the family over the phone or a conference call to explain the nature of the study, as detailed in the written informed consent. A witness who was not part of this research study was present during the verbal consenting process and documentation was completed in the patient chart.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets used and analyzed during the current report are available from the corresponding author on reasonable request.
List of Abbreviations
- APACHE II
- Acute Physiology and Chronic Health Evaluation II
- CRC
- Clinical Research Committee
- CAM-ICU
- Confusion Assessment Method for the ICU
- DNR
- Do-not-resuscitate
- ECMO
- Extracorporeal membrane oxygenation
- HR
- Heart rate
- ICU
- Intensive care unit
- IQR
- Interquartile range
- IRB
- Institutional Review Board
- KFSH&RC
- King Faisal Specialist Hospital and Research Centre
- LOS
- Length of stay
- MV
- Mechanical ventilation
- ORA
- Office of Research Affair
- PADIS
- Pain,Agitation,Sedation,Delirium, Immobility, and Sleep
- RCT
- Randomized controlled trial
- PF ratio
- Ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen
- REC
- Research Ethics Committee
- REDCap
- Research Electronic Data Capture
- RASS
- Richmond Agitation-Sedation Scale
- SOFA
- Sequential Organ Failure Assessment
- SAT
- Spontaneous awakening trial
- SBT
- Spontaneous breathing trial
- SBP
- Systolic blood pressure
